4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Overactive Bladder by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 141 ongoing clinical trials involving Overactive Bladder
Of the 141 trials,42 trials are in Phase III
Furthermore, 38 trials are in Phase IV

Number of ongoing Clinical Trials (for drugs) involving Overactive Bladder by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Overactive Bladder, a Genito Urinary System and Sex Hormones indication. The largest number of ongoing clinical trials for Overactive Bladder is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions engaged in Overactive Bladder-related drug trials.

Urovant Sciences Inc: The leading ongoing Overactive Bladder related clinical trial sponsor

Urovant Sciences Inc is the top sponsor for Overactive Bladder-related ongoing clinical trials.

Far Eastern Memorial Hospital, Far Eastern Memorial Hospital, Shiga University of Medical Science, Xiyuan Hospital of China Academy of Chinese Medical Sciences, and Astellas Pharma Inc are among other notable clinical trial sponsors involved in Overactive Bladder. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Overactive Bladder

Mirabegron (Betanis, Myrbetriq, YM178), Onabotulinumtoxin A (Botox), and Solifenacin succinate (Vesicare, Astrif, Vesikur) are among the key marketed drugs involving Overactive Bladder.

Mirabegron (Betanis, Myrbetriq, YM178) is a smooth muscle relaxant, formulated as extended release/prolonged release tablets, film coated tablets and granules for suspension for oral route of administration. It functions via Beta 3 Adrenergic Receptor (Beta 3 Adrenoreceptor or ADRB3) Agonist mechanism of action. Mirabegron is indicated for the treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome. Myrbetriq granules is indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older and tablets are indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older and weighing 35 kg or more. Mirabegron was first approved in 2011 and is marketed globally including the US, France, Germany, and Japan by several pharma giants including Astellas Pharma Inc.

Solifenacin succinate (Vesicare, Astrif, Vesikur) is a urinary antispasmodic agent, belongs to anticholinergic class. It functions via Muscarinic Acetylcholine Receptor M3 (CHRM3) Antagonist mechanism of action. It is formulated as tablets and film coated tablets and suspension for oral route of administration. Solifenacin is indicated for the treatment for the relief of symptoms of urinary frequency, urinary urgency, or urge urinary incontinence associated with an overactive bladder, and for the treatment of neurogenic detrusor overactivity and idiopathic overactive bladder in pediatrics. Solifenacin succinate was first approved in 2004 and is marketed globally including the US, France, Germany, China, and Japan by Astellas Pharma Inc and its subsidiaries.